These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 23781960)

  • 1. Efficacy and safety of Privigen(®) in patients with chronic inflammatory demyelinating polyneuropathy: results of a prospective, single-arm, open-label Phase III study (the PRIMA study).
    Léger JM; De Bleecker JL; Sommer C; Robberecht W; Saarela M; Kamienowski J; Stelmasiak Z; Mielke O; Tackenberg B; Shebl A; Bauhofer A; Zenker O; Merkies IS;
    J Peripher Nerv Syst; 2013 Jun; 18(2):130-40. PubMed ID: 23781960
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of IVIG in CIDP: Combined data of the PRIMA and PATH studies.
    Merkies ISJ; van Schaik IN; Léger JM; Bril V; van Geloven N; Hartung HP; Lewis RA; Sobue G; Lawo JP; Durn BL; Cornblath DR; De Bleecker JL; Sommer C; Robberecht W; Saarela M; Kamienowski J; Stelmasiak Z; Tackenberg B; Mielke O;
    J Peripher Nerv Syst; 2019 Mar; 24(1):48-55. PubMed ID: 30672091
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An international multicenter efficacy and safety study of IqYmune in initial and maintenance treatment of patients with chronic inflammatory demyelinating polyradiculoneuropathy: PRISM study.
    Nobile-Orazio E; Pujol S; Kasiborski F; Ouaja R; Corte GD; Bonek R; Cocito D; Schenone A
    J Peripher Nerv Syst; 2020 Dec; 25(4):356-365. PubMed ID: 32808406
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Restabilization treatment after intravenous immunoglobulin withdrawal in chronic inflammatory demyelinating polyneuropathy: Results from the pre-randomization phase of the Polyneuropathy And Treatment with Hizentra study.
    Mielke O; Bril V; Cornblath DR; Lawo JP; van Geloven N; Hartung HP; Lewis RA; Merkies ISJ; Sobue G; Durn B; Shebl A; van Schaik IN;
    J Peripher Nerv Syst; 2019 Mar; 24(1):72-79. PubMed ID: 30672067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (The PATH Study): study protocol for a randomized controlled trial.
    van Schaik IN; van Geloven N; Bril V; Hartung HP; Lewis RA; Sobue G; Lawo JP; Mielke O; Cornblath DR; Merkies IS;
    Trials; 2016 Jul; 17(1):345. PubMed ID: 27455854
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized trial of three IVIg doses for treating chronic inflammatory demyelinating polyneuropathy.
    Cornblath DR; van Doorn PA; Hartung HP; Merkies ISJ; Katzberg HD; Hinterberger D; Clodi E;
    Brain; 2022 Apr; 145(3):887-896. PubMed ID: 35038723
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and economic comparison of an individualised immunoglobulin protocol vs. standard dosing for chronic inflammatory demyelinating polyneuropathy.
    Rajabally YA; Afzal S
    J Neurol; 2019 Feb; 266(2):461-467. PubMed ID: 30556098
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined intravenous immunoglobulin and methylprednisolone as induction treatment in chronic inflammatory demyelinating polyneuropathy (OPTIC protocol): a prospective pilot study.
    Adrichem ME; Bus SR; Wieske L; Mohammed H; Verhamme C; Hadden R; van Schaik IN; Eftimov F
    Eur J Neurol; 2020 Mar; 27(3):506-513. PubMed ID: 31571349
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Timing and course of clinical response to intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy.
    Latov N; Deng C; Dalakas MC; Bril V; Donofrio P; Hanna K; Hartung HP; Hughes RA; Merkies IS; van Doorn PA;
    Arch Neurol; 2010 Jul; 67(7):802-7. PubMed ID: 20457948
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hyaluronidase-facilitated subcutaneous immunoglobulin 10% as maintenance therapy for chronic inflammatory demyelinating polyradiculoneuropathy: The ADVANCE-CIDP 1 randomized controlled trial.
    Bril V; Hadden RDM; Brannagan TH; Bar M; Chroni E; Rejdak K; Rivero A; Andersen H; Latov N; Levine T; Pasnoor M; Sacconi S; Souayah N; Anderson-Smits C; Duff K; Greco E; Hasan S; Li Z; Yel L; Ay H
    J Peripher Nerv Syst; 2023 Sep; 28(3):436-449. PubMed ID: 37314318
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomised, multi-centre phase III study of 3 different doses of intravenous immunoglobulin 10% in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ProCID trial): Study design and protocol.
    Cornblath DR; Hartung HP; Katzberg HD; Merkies ISJ; van Doorn PA
    J Peripher Nerv Syst; 2018 Jun; 23(2):108-114. PubMed ID: 29603842
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunomodulation of inflammatory leukocyte markers during intravenous immunoglobulin treatment associated with clinical efficacy in chronic inflammatory demyelinating polyradiculoneuropathy.
    Dyer WB; Tan JC; Day T; Kiers L; Kiernan MC; Yiannikas C; Reddel S; Ng K; Mondy P; Dennington PM; Dean MM; Trist HM; Dos Remedios C; Hogarth PM; Vucic S; Irving DO
    Brain Behav; 2016 Oct; 6(10):e00516. PubMed ID: 27781132
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunomodulatory treatment other than corticosteroids, immunoglobulin and plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy.
    Mahdi-Rogers M; Brassington R; Gunn AA; van Doorn PA; Hughes RA
    Cochrane Database Syst Rev; 2017 May; 5(5):CD003280. PubMed ID: 28481421
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment timing and choice of outcome measure in determining treatment response in chronic inflammatory demyelinating polyneuropathy: A post hoc analysis of the PRISM trial.
    Rajabally YA; Ouaja R; Kasiborski F; Pujol S; Nobile-Orazio E
    Muscle Nerve; 2022 Nov; 66(5):562-567. PubMed ID: 36057106
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Longer-term effects of intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: Who benefits?
    Terhoeven P; Seybold J; Utz KS; Nickel FT; Lee DH; Linker RA
    J Neurol Sci; 2020 Dec; 419():117169. PubMed ID: 33035867
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of relapse by inflammatory Rasch-built overall disability scale status in the PATH study of subcutaneous immunoglobulin in chronic inflammatory demyelinating polyneuropathy.
    Merkies ISJ; van Schaik IN; Bril V; Hartung HP; Lewis RA; Sobue G; Lawo JP; Mielke O; Cornblath DR;
    J Peripher Nerv Syst; 2022 Jun; 27(2):159-165. PubMed ID: 35266243
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravenous immunoglobulin for maintenance treatment of chronic inflammatory demyelinating polyneuropathy: a multicentre, open-label, 52-week phase III trial.
    Kuwabara S; Mori M; Misawa S; Suzuki M; Nishiyama K; Mutoh T; Doi S; Kokubun N; Kamijo M; Yoshikawa H; Abe K; Nishida Y; Okada K; Sekiguchi K; Sakamoto K; Kusunoki S; Sobue G; Kaji R;
    J Neurol Neurosurg Psychiatry; 2017 Oct; 88(10):832-838. PubMed ID: 28768822
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral fingolimod for chronic inflammatory demyelinating polyradiculoneuropathy (FORCIDP Trial): a double-blind, multicentre, randomised controlled trial.
    Hughes R; Dalakas MC; Merkies I; Latov N; Léger JM; Nobile-Orazio E; Sobue G; Genge A; Cornblath D; Merschhemke M; Ervin CM; Agoropoulou C; Hartung HP;
    Lancet Neurol; 2018 Aug; 17(8):689-698. PubMed ID: 30001923
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of subcutaneous immunoglobulin on quality of life in patients with chronic inflammatory demyelinating polyneuropathy previously treated with intravenous immunoglobulin.
    Vu T; Anthony N; Alsina R; Harvey B; Schleutker A; Farias J; Dang S; Suresh N; Gooch C
    Muscle Nerve; 2021 Sep; 64(3):351-357. PubMed ID: 34076265
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial.
    Hughes RA; Donofrio P; Bril V; Dalakas MC; Deng C; Hanna K; Hartung HP; Latov N; Merkies IS; van Doorn PA;
    Lancet Neurol; 2008 Feb; 7(2):136-44. PubMed ID: 18178525
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.